The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PMV Pharmaceuticals, Inc
Mayo Clinic
Sichuan Enray Pharmaceutical Sciences Company
M.D. Anderson Cancer Center
Kidney Cancer Research Bureau
Second Life Therapeutics
Eli Lilly and Company
Inhibrx Biosciences, Inc
VM Oncology, LLC
Takeda
Roswell Park Cancer Institute
Eli Lilly and Company
LigaChem Biosciences, Inc.
A2 Biotherapeutics Inc.
Incyte Corporation
Turning Point Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Marengo Therapeutics, Inc.
Cancer Research UK
Hoffmann-La Roche
Gustave Roussy, Cancer Campus, Grand Paris
Intensity Therapeutics, Inc.
NextCure, Inc.
NantCell, Inc.
Second Affiliated Hospital of Guangzhou Medical University
iTeos Therapeutics
Turning Point Therapeutics, Inc.
NextCure, Inc.
Fusion Pharmaceuticals Inc.
Klus Pharma Inc.
Kineta Inc.
Incyte Corporation
Incyte Corporation
Petra Pharma
Harbin Medical University
Centocor, Inc.
Memorial Sloan Kettering Cancer Center
Siemens Molecular Imaging